https://www.selleckchem.com/pr....oducts/Aloxistatin.h
735, P = 0.015) and renal dysfunction group (F = 16.002, P 0.001). Renal function should be monitored in patients prescribed with AMI, particularly in those taking clozapine. Plasma concentration per dose values can be considered as a risk factor of QTc interval prolongation. The founding help clinicians to analyze the risk of QTc prolongation before prescribing AMI and to monitor QTc prolongation during AMI therapy. Renal function should be monitored in patients prescribed with AMI, particularly in those taking clozapine. Plas
Like
Comment
Share
